Provided by Tiger Trade Technology Pte. Ltd.

Cellect Biotechnology

13.17
0.0000
Volume:- -
Turnover:- -
Market Cap:12.91M
PE:-2.56
High:13.17
Open:13.17
Low:13.17
Close:13.17
52wk High:35.52
52wk Low:6.88
Shares:980.43K
Float Shares:942.86K
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.1505
EPS(LYR):-6.1107
ROE:-120.42%
ROA:-47.79%
PB:8.34
PE(LYR):-2.16

Loading ...

Company Profile

Company Name:
Cellect Biotechnology
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
As of October 28, 2021, Cellect Biotechnology Ltd. was acquired by Quoin Pharmaceuticals, Inc., in a reverse merger transaction. Cellect Biotechnology Ltd., a biotechnology company, engages in developing ApoGraft, a technology platform that functionally selects stem cells to enhance the safety of regenerative medicine and stem cell therapies in Israel. The company develops ApoTainer, a kit for hematopoietic stem cell transplantation procedures. It has collaborations with the denovoMATRIX group of the Technische Universität Dresden to conduct examinations into the tentative synergy between ApoGraft and denovoMAtrix technology for the purpose of evaluating collaborative development of products for regenerative medicine; Cell2in Inc. to conduct scientific evaluations combining ApoGraft with Cell2in's identification technology FreSHtracer, which monitors stem cell quality by utilizing a fluorescent dye to characterize their oxidative stress state; and XNK therapeutics to focus on the development of cell-based therapeutics from NK cells. The company was formerly known as Cellect Biomed Ltd. and changed its name to Cellect Biotechnology Ltd. in July 2016. Cellect Biotechnology Ltd. was incorporated in 1986 and is headquartered in Kfar Saba, Israel.